Combination Adjuvant Chemotherapy + Radiation Therapy vs Radiation Alone for High Risk Endometrial Carcinoma: Final Report From PORTEC-3

June 2-6, 2017; Chicago, Illinois
Combination RT + CT improved 5-year failure-free survival by 11% in patients with stage III disease.
Format: Microsoft PowerPoint (.ppt)
File Size: 665 KB
Released: June 4, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Downloadable slideset on the latest clinical data on the management of endometrial cancer, from Clinical Care Options (CCO)

person default Linda R. Duska, MD, MPH Released: June 18, 2021

Phase III OUTBACK study of standard chemoradiation ± adjuvant chemotherapy in locally advanced cervical cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 11, 2021

Randomized TOTEM trial of intensive vs minimalist follow-up in patients treated for endometrial cancer from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 10, 2021

Phase II study of niraparib with/without dostarlimab shows a CBR of 31.8% vs 20.0% with monotherapy in recurrent EC from ASCO 2021 as reported by Clinical Care Options (CCO)

Released: June 8, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue